TY - JOUR
T1 - Treatment de-escalation for HPV-driven oropharyngeal cancer
T2 - Where do we stand?
AU - Mirghani, Haitham
AU - Blanchard, Pierre
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2018/1/1
Y1 - 2018/1/1
N2 - HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies.
AB - HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies.
KW - Cancer/neoplasm
KW - Human papillomavirus (HPV)
KW - Oropharynx/oropharyngeal
KW - Treatment de-escalation/de-intensification
UR - http://www.scopus.com/inward/record.url?scp=85052191415&partnerID=8YFLogxK
U2 - 10.1016/j.ctro.2017.10.005
DO - 10.1016/j.ctro.2017.10.005
M3 - Review article
AN - SCOPUS:85052191415
SN - 2405-6308
VL - 8
SP - 4
EP - 11
JO - Clinical and Translational Radiation Oncology
JF - Clinical and Translational Radiation Oncology
ER -